Key Takeaways
- • Blue Matter, a life sciences consulting firm backed by Baird Capital, has acquired Cognite, a London-based global healthcare communications agency, according to PE Hub.
- • Cognite serves pharmaceutical and biotech companies with scientific, medical and commercial communications, with a focus on complex specialty markets such as rare diseases.
- • The deal extends Blue Matter's communications capabilities and marks another step in its buy-and-build strategy following prior acquisitions of Sam Brown and AIM.
- • The transaction terms, including purchase price, were not disclosed in the available reporting.
Summary
Blue Matter, a strategic consulting firm serving the life sciences industry and backed by Baird Capital, has acquired Cognite, a London-based global healthcare communications agency, according to PE Hub. The deal was announced in a brief report on PE Hub's Europe deals coverage.
Cognite describes itself as a leading healthcare communications agency that exists to bring science to life. The firm serves pharmaceutical and biotech companies with scientific, medical and commercial communications, with a particular focus on complex specialty markets such as rare diseases and transformative medicines. According to Blue Matter's announcement, the acquisition represents a significant step in strengthening the company's growing range of communications capabilities.
Blue Matter provides consultancy services to the global pharmaceutical sector, principally in product and portfolio strategy. The Cognite acquisition continues a buy-and-build approach that has included recent transactions for healthcare communications firms. Blue Matter previously acquired Wayne, Pennsylvania-based Sam Brown Inc, a healthcare communications and PR agency, and, months after Baird Capital's investment, the Dutch life science boutique AIM.
Baird Capital has also closed a continuation vehicle involving Blue Matter Consulting LLC, drawn from its $450 million Baird Capital Global Fund III, which supports the company's continued expansion. Financial terms of the Cognite transaction were not disclosed in the sources reviewed.
Cognite describes itself as a leading healthcare communications agency that exists to bring science to life. The firm serves pharmaceutical and biotech companies with scientific, medical and commercial communications, with a particular focus on complex specialty markets such as rare diseases and transformative medicines. According to Blue Matter's announcement, the acquisition represents a significant step in strengthening the company's growing range of communications capabilities.
Blue Matter provides consultancy services to the global pharmaceutical sector, principally in product and portfolio strategy. The Cognite acquisition continues a buy-and-build approach that has included recent transactions for healthcare communications firms. Blue Matter previously acquired Wayne, Pennsylvania-based Sam Brown Inc, a healthcare communications and PR agency, and, months after Baird Capital's investment, the Dutch life science boutique AIM.
Baird Capital has also closed a continuation vehicle involving Blue Matter Consulting LLC, drawn from its $450 million Baird Capital Global Fund III, which supports the company's continued expansion. Financial terms of the Cognite transaction were not disclosed in the sources reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.